Are we failing to provide adequate rescue medication to children at risk of prolonged convulsive seizures in schools?

J Helen Cross,1,2 Suzanne Wait,3 Alexis Arzimanoglou,4 Ettore Beghi,5 Christine Bennett,6 Lieven Lagae,7 Janet Mifsud,8 Dieter Schmidt,9 Gordon Harvey10

ABSTRACT
Objective This paper explores the issues that arise from the discussion of administering rescue medication to children who experience prolonged convulsive seizures in mainstream schools in the UK.

Situation analysis Current guidelines recommend immediate treatment of children with such seizures (defined as seizures lasting more than 5 min) to prevent progression to status epilepticus and neurological morbidity. As children are unconscious during prolonged convulsive seizures, whether or not they receive their treatment in time depends on the presence of a teacher or other member of staff trained and able to administer rescue medication. However, it is thought that the situation varies between schools and depends mainly on the goodwill and resources available locally.

Recommendations A more systematic response is needed to ensure that children receive rescue medication regardless of where their seizure occurs. Possible ways forward include: greater use of training resources for schools available from epilepsy voluntary sector organisations; consistent, practical information to schools; transparent guidance outlining a clear care pathway from the hospital to the school; and implementation and adherence to each child’s individual healthcare plan.

Implications Children requiring emergency treatment for prolonged convulsive seizures during school hours test the goals of integrated, person-centred care as well as joined-up working to which the National Health Service (NHS) aspires. As changes to the NHS come into play and local services become reconfigured, every effort should be made to take account of the particular needs of this vulnerable group of children within broader efforts to improve the quality of paediatric epilepsy services overall.

INTRODUCTION
Significant shortfalls in service delivery for children with epilepsy have recently been reported in the UK.1 2 A particularly vulnerable group are children who experience prolonged convulsive seizures, defined as seizures lasting 5 min or more.3 National Institute for Health and Clinical Excellence (NICE) guidelines4 recommend immediate treatment of children with such seizures to prevent progression to status epilepticus and neurological morbidity.5 6

Most seizures occur outside of the hospital setting. Children are often unconscious during prolonged convulsive seizures; thus, whether or not they receive their treatment in time depends on the presence of a caregiver trained and able to administer rescue medication. This paper explores the issues that arise from the discussion of administering rescue medication in mainstream schools in the UK in the hope of raising awareness of unmet needs in this area.

PROLONGED CONVULSIVE SEIZURES
IN CHILDREN
Seizures that last more than 5 min are unlikely to stop on their own;7 thus, guidelines recommend that rescue medication (buccal midazolam or, if preferred or if buccal midazolam is unavailable, rectal diazepam) be administered for any convulsive seizure lasting 5 min or more in a community setting.8 Delays in treatment increase the risk of progression to status epilepticus,8 which may result in possible cognitive deficits5 8 and even death.10

The NICE guidelines for the diagnosis and management of the epilepsies in primary and secondary care recommend that all relevant caregivers, who include parents, teachers and other school staff, receive dedicated training to be able to administer rescue medication as promptly as possible to children according to a prespecified protocol.4 Guidance on medicines management in mainstream schools also
Parents submit a request to the school for their child to receive prescribed medication as needed. They provide all the necessary medical information from the treating physician.

An individualised healthcare plan is agreed among the parents, school head, local health service and school doctor or nurse (if available).

This is supported by a school policy on the administration of medicines and/or epilepsy.

Teachers (or other staff members) are asked to volunteer to take responsibility for administering the medication in question.

They receive specific training to do so either from the school nurse or local health service.

## ARE SCHOOLS OBLIGED TO ADMINISTER RESCUE MEDICATION TO CHILDREN?

In the UK, children with epilepsy are considered disabled for the purposes of the Equality Act of 2010 and are thus protected from discrimination in terms of admission and participation in school activities. Under the Education and Inspections Act of 2006, schools must make all arrangements necessary to meet the needs of any child requiring medical assistance during school hours. However, it is not a legal requirement for school staff to administer medicines to children (this role is entirely voluntary). Most teachers’ unions actively discourage their members from accepting responsibility for doing so claiming that this falls outside of their duty of care and that they may be liable if anything goes wrong. 

What happens in practice? Little published evidence exists on the experience of children who require rescue medication at school but the situation is thought to vary between schools. Insights from epilepsy specialists suggest that schools often react with panic and fear when faced with a child having a prolonged convulsive seizure. Fear of liability is a major barrier to overcome (PERFECT, data on file, 2012).

Some schools call an ambulance for every prolonged convulsive seizure that occurs at school, potentially causing treatment delays and subsequent complications for the child. Others may expect parents to be permanently on call in case their child experiences a seizure during school hours, forcing many parents to abandon full-time employment for the safety of their child. Both situations may threaten the social integration of the child and lead to stigmatisation.

Certain requirements must be met for the needs of these children to be addressed during school hours, the most important being training, clear information and communication, resources and accountability.

## TRAINING, INFORMATION, RESOURCES AND ACCOUNTABILITY

Several studies point to inadequate training on epilepsy in schools. A survey of schools carried out by Epilepsy Action in 2012 found that over a quarter had not received any epilepsy training in the past 3 years. One in six teachers said that pupils with epilepsy at their school either did not have an individual healthcare plan or that they did not know if they had one.

Better information and communication to schools is the key. Charitable organisations, in particular Young Epilepsy, the Joint Epilepsy Council and Epilepsy Action, have played an essential role in providing helpful resources on rescue medication to parents and schools in the form of guidance, templates and training courses. But implementing training requires firm commitment from staff volunteering to be trained as well as the school. For example, the Joint Epilepsy Council recommends two full days of training within school settings to ensure competency.

Resources outside of the educational system are also critical. NICE recommends that every child with a diagnosis of epilepsy should have a dedicated paediatric epilepsy specialist nurse (ESN) who acts as the liaison to the child’s school and provides support and training in the child’s home and school. Unfortunately, poor resourcing of paediatric ESNs is a longstanding issue, despite their proven role in reducing the number of admissions to hospital for children. In all, 47% of the paediatric epilepsy centres audited in the Royal College of Paediatrics and Child Health Epilepsy12 (2012) survey had no ESN. Without a dedicated ESN, parents are left as the sole link between the health service and the educational system, yet they may lack the necessary skills and information to fulfil such a role.

The issue of accountability is also important. NICE guidelines recommend that only children who have had a previous episode of prolonged convulsive seizures should be prescribed rescue medication. The implication of this ‘responsible prescribing’ is that schools are only asked to invest in training to administer rescue medication when they have a pupil who is known to be at risk.

## THE WAY FORWARD

Children requiring emergency treatment for prolonged convulsive seizures during school hours test the goals of integrated, person-centred care as well as joined-up working to which the National Health Service (NHS) aspires. Whether a child receives rescue medication at school currently depends mostly on the goodwill and resources available at each school. Consequently, some children are effectively denied their basic legal right to mainstream education, a clearly unacceptable situation.

This situation is not unique to the UK and some possible ways forward are suggested in box 2. They include: greater use of training resources for schools available from epilepsy voluntary sector organisations; consistent, practical information to schools; transparent guidance outlining a clear care pathway from the hospital to the school; and implementation and adherence to each child’s individual healthcare plan.

Of course, the recommendations outlined above are not only relevant to children with epilepsy. Lack of support from schools is thought to be the main reason why diabetes specialists refrain from prescribing certain forms of insulin to children in the UK. And across Europe, organisations representing the interests of children with asthma, diabetes, epilepsy and anaphylaxis have joined forces to campaign for greater recognition of the medical needs of children with these conditions in schools (eg, [http://www.medicalconditionsatschool.org.uk](http://www.medicalconditionsatschool.org.uk)).

It is important to recognise that inadequacies in the current system are due to lack of resources and unclear guidance as opposed to lack of good will or professionalism on the part of schools and healthcare professionals. There are many promising
Box 2 Areas for improvement in the management of children with prolonged seizures in schools

- Treating specialists should work with voluntary sector organisations to provide clear and practical information to schools on prolonged convulsive seizures and rescue medication.
- Every child with a history of prolonged convulsive seizures should have an individual healthcare plan put in place at his or her school.
- A clear link should be established, ideally via an epilepsy specialist nurse, between the treating physician and the school for each child who requires rescue medication.
- All caregivers responsible for a child at risk of prolonged convulsive seizures should receive specific training on their rescue medication.
- Comprehensive guidance that spans across the health and educational sector is needed to ensure that children at risk of prolonged convulsive seizures are treated as quickly as possible regardless of where the seizure occurs.
- More empirical data are needed to gain a better understanding of the experience of children who experience prolonged convulsive seizures at school, including the perspective of teachers. The role played by emergency services also needs to be clarified.

Adapted from Wait et al.25

examples of primary care trusts working together with local educational authorities to find workable and sustainable solutions. As changes to the NHS come into play and local services become reconfigured, every effort should be made to maintain such collaborations. And more needs to be done generally to become recon

Author affiliations

1UCL Institute of Child Health, Great Ormond Street Hospital NHS Foundation Trust, London, UK
2Young Epilepsy, Lingfield, UK
3SHW Health Ltd, London, UK
4Epilepsy, Sleep and Paediatric Neurophysiology Department, University Hospitals of Lyon (HCL), Lyon, France
5IRCCS, Institute for Pharmacological Research “Mario Negri”, Milano, Italy
6Hull and East Yorkshire Hospitals NHS Trust, Hull, UK
7Neuro-musculo-skeletal Research Unit, University of Leuven, Leuven, Belgium
8Department of Clinical Pharmacology and Therapeutics, Faculty of Medicine and Surgery, University of Malta, Msida, Malta
9Epilepsy Research Group, Berlin, Germany
10ViroPharma SPRL, Brussels, Belgium

Contributors This paper was drafted as part of the Practices in Emergency and Rescue medication for Epilepsy managed with Community administered Therapy (PERFECT) initiative, which aims to gain a better understanding of how prolonged acute convulsive seizures in children are managed in non-hospital settings across Europe. All coauthors are members of the PERFECT Steering Committee and have participated in developing the study methodology and interpretation of findings. A first draft of this manuscript was written by SW and was reviewed by all other coauthors. HC is the guarantor of the paper.

Funding This paper was drafted as part of the Practices in Emergency and Rescue medication for Epilepsy managed with Community administered Therapy (PERFECT) initiative, which is funded by ViroPharma SPRL.

Competing interests We have read and understood the BMJ Group policy on declaration of interests and declare the following interests: Professor Cross holds an endowed Chair through University College, London. She is a member of the PERFECT steering committee and receives honoraria from ViroPharma SPRL for this role. She has sat on Advisory Boards for Eisai and ViroPharma and also sits on a safety monitoring board for GlaxoSmithKline for which honoraria are paid to UCL-ICH Neurosciences Unit. She worked as Clinical Advisor to the update of the NICE guidelines on the diagnosis and management of the epilepsies (2009–2012) and currently as Clinical Advisor to the Children’s Epilepsy Surgery Service for which remuneration was and is made to her department. She is a recipient of research grants from Action medical research, Great Ormond Street Hospital Charity and Epilepsy Research UK. Suzanne Wait is Director of SHW Health Limited and receives consultancy fees from ViroPharma SPRL. She is a member of the PERFECT steering committee. Alexis Arzimanoglou is Director of the Epilepsy, Sleep and Paediatric Neurophysiology department, University Hospitals of Lyon (France). He is a member of the PERFECT steering committee and receives honoraria from ViroPharma SPRL for this role. In the past 36 months, he has received speaker’s or consultancy fees from Cyberonics, Eisai, GlaxoSmithKline, UCB Pharma and ViroPharma. He also sits on a safety monitoring board for UCB and received educational and European Community grants for which remuneration was made to HCL or to a research association of his department. Ettore Beghi serves on the editorial advisory boards of Epilepsia, Amyotrophic Lateral Sclerosis, Clinical Neurology & Neurosurgery, and Neuroepidemiology. He is a member of the PERFECT steering committee and receives honoraria from ViroPharma SPRL for this role. He has received funding for travel and speaker honoraria from UCB-Pharma, Sanofi-Aventis, GSK, Eisai; funding from GSK for educational presentations; and from AIFA, Sanofi-Aventis, Janssen-Cilag, Eisai, Lombardy Region, Istituto Superiore di Sanità and American ALS Association for the coordinating activity of RCTs and observational study protocols. Christine Bennett has no conflicts of interest. She is a member of the PERFECT steering committee and receives honoraria from ViroPharma SPRL for this role. Lieven Lagae has received consultancy honoraria from ViroPharma and is a member of the PERFECT steering committee, for which he receives honoraria from ViroPharma SPRL. Dr Janet Milhoud has received consultancy honoraria from ViroPharma during the past year. She is a member of the PERFECT steering committee and receives honoraria from ViroPharma SPRL for this role. Professor Dieter Schmidt is a member of the PERFECT steering committee and receives honoraria from ViroPharma SPRL for this role. He has received hospitality, speaker fees or consultancy honoraria from ViroPharma, GSK, Sun Pharma, Novartis and UCB Pharma during the past year. Gordon Harvey is an employee of ViroPharma SPRL and is a member of the PERFECT steering committee.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement This paper was drafted as part of the Practices in Emergency and Rescue medication for Epilepsy managed with Community administered Therapy (PERFECT) initiative. This paper draws from the first two phases of PERFECT: a review of clinical guidelines and non-clinical guidance relevant to the management of prolonged seizures in children in non-hospital settings, which has been published (Wait et al, Eur J Paediatr Neurol 201325), and a survey of physicians who treat children with prolonged seizures (publication in press). A third phase consisting of a survey of children with prolonged seizures and their parents will report and be published in full in early 2014.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

REFERENCES

4 National Institute for Health and Clinical Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary


15 Education and Inspections Act of 2006, UK.


23 Champions for Childhood Epilepsy Campaign training DVD. 2011.


27 UK Children With Diabetes Advocacy Group. Every child matters: or do they? Children with type 1 diabetes are being let down by lack of support in school. 2007.
Are we failing to provide adequate rescue medication to children at risk of prolonged convulsive seizures in schools?

J Helen Cross, Suzanne Wait, Alexis Arzimanoglou, Ettore Beghi, Christine Bennett, Lieven Lagae, Janet Mifsud, Dieter Schmidt and Gordon Harvey

Arch Dis Child 2013 98: 777-780 originally published online July 30, 2013 doi: 10.1136/archdischild-2013-304089

Updated information and services can be found at:
http://adc.bmj.com/content/98/10/777

These include:

References
This article cites 10 articles, 2 of which you can access for free at:
http://adc.bmj.com/content/98/10/777#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Open access (206)
Child health (3922)
Epilepsy and seizures (391)
Epidemiologic studies (1818)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/